Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply ...

Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% ...

Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.

A team of scientists at the Indiana University School of Medicine has identified that an eye condition affecting the retina, the light-sensing tissue in the back of the eye, may serve as an early ...

APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (RTGN) [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging ...

Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (KPRX) (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...

RetinalGenix is developing a portfolio of non‑invasive imaging solutions, including a portable Retinal Imaging Screening Device and the RetinalCam remote monitoring system, designed for use without ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...